Search General Info
Search Education
Search Partnering Companies
High return potential associated with super low risk!
As a biotech start-up, similar to other bio start-ups, Aavocyte has a very high return potential. What is different from most other start-ups is that Aavocyte enjoys an inherent value of super low risk in favor of its investors, which makes Aavocyte a hard-to-find investment opportunity in biotech start-ups.
Series A major terms
• Extra investor protection by satisfying the following conditions before using the investment raised
o IND clinical trials must be allowed by FDA, and
o Total fund raised must be at least $5M
• Maximum common shares to be issued: up to 1,000,000 shares (1/3 total outstanding shares after funding).
• Unit price: $20/share
• Minimum investment: $500,000
• Minimum closing: $5M
If closed with $5M for A, Round B is needed before pre-IPO funding of Round C. It is target to launch Series C together with IPO in 2021-2022.
As a biotech start-up, similar to other bio start-ups, Aavocyte has a very high return potential. What is different from most other start-ups is that Aavocyte enjoys an inherent value of super low risk in favor of its investors, which makes Aavocyte a hard-to-find investment opportunity in biotech start-ups.
Series A major terms
• Extra investor protection by satisfying the following conditions before using the investment raised
o IND clinical trials must be allowed by FDA, and
o Total fund raised must be at least $5M
• Maximum common shares to be issued: up to 1,000,000 shares (1/3 total outstanding shares after funding).
• Unit price: $20/share
• Minimum investment: $500,000
• Minimum closing: $5M
If closed with $5M for A, Round B is needed before pre-IPO funding of Round C. It is target to launch Series C together with IPO in 2021-2022.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Washington
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Cell therapy for Prostate Cancer
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved